Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Thymosin Alpha 1
Beginner tier: 1.6 mg, 2x/week · clinical trials
Also known as: Tα1, Ta1, Thymalfasin
Approved in 35 countries, studied in over 11,000 patients across 30+ clinical trials. Thymosin Alpha 1 (Tα1) is a 28-amino-acid peptide your thymus gland produces to prime T-cell and NK cell immunity. The Zadaxin label established 1.6 mg subcutaneously twice weekly as the clinical standard for hepatitis B, with HBeAg seroconversion rates reaching 30 to 40% versus 18% on placebo (PMC4688733). The FDA restricted US compounding access in 2023, though a 2024 review [1] covering the full trial evidence base challenged that decision directly. Community use now centers on immune support, long COVID recovery, and longevity protocols.
What Is Thymosin Alpha 1?
Thymosin Alpha 1 (Tα1, CAS 62304-98-7, molecular weight 3108 Da) is a 28-amino-acid acetylated peptide naturally produced by the thymus gland, approved in 35 countries under the brand name Zadaxin. The US restricted it from compounding pharmacies, creating a regulatory contradiction that defines its story. It binds Toll-like receptors TLR2 and TLR9 on dendritic cells, triggering downstream T-cell differentiation and NK cell activation through MyD88-dependent signaling. The clinical dose is 1.6 mg (1600 mcg) subcutaneously twice weekly, established by decades of Zadaxin prescribing data.
The hepatitis B trials built the evidence base. A Phase III RCT (PMC4688733) showed HBeAg seroconversion at 30 to 40% versus 18% on placebo at 12 months. The Dinetz and Lee 2024 review [1] pulled together 30+ trials enrolling 11,000+ subjects and found consistent immune activation across indications. A separate 2024 meta-analysis [2] of 39 RCTs in acute COPD exacerbations (3,329 patients) confirmed improved FEV1, oxygenation, and reduced hospital stay.
Community use has expanded well past hepatitis. Longevity practitioners, long COVID patients, and ME/CFS communities use the same 1600 mcg twice-weekly protocol for T-cell restoration. The practical limitation: Tα1 produces no subjective "feel." Bloodwork (CBC with differential, CD4/CD8 ratio) is the only way to confirm it's working.
The TESTS Phase 3 sepsis trial (n=1,106)[3] missed its primary mortality endpoint (HR 0.99, p=0.93). That null result is worth knowing. It didn't undermine the hepatitis or immune-support evidence, but it set a boundary on what Tα1 can do in acute critical care.
How Thymosin Alpha 1 Works
Tα1 binds TLR2 and TLR9 on dendritic cells. That initial contact triggers MyD88-dependent signaling cascades that upregulate MHC class I and class II expression, improving how dendritic cells present antigens to T cells.
Downstream effects split across two immune arms. On the adaptive side, Tα1 drives maturation of CD4+ helper T cells and CD8+ cytotoxic T cells from immature thymic precursors. Even in aged or immunocompromised individuals, it partially restores thymic output of mature T-cell subsets from CD4-/CD8- progenitors. NK cell cytotoxicity increases in parallel.
The p38 MAPK and NF-κB pathways carry the cytokine signal. Tα1 pushes Th1-type cytokine production (IL-2, IL-12, IFN-γ) while dampening excessive Th2 responses. This is the immune-balancing property that separates Tα1 from pure immune stimulants. It upregulates regulatory T cells and modulates IDO (indoleamine 2,3-dioxygenase) expression, which helps prevent autoimmune overshoot.
At the cellular level, Tα1 boosts oxidative killing in macrophages and neutrophils by stimulating NADPH oxidase activity. Pathogens get cleared faster. A single injection triggers signaling cascades on dendritic cells that activate T-cell differentiation responses lasting days to weeks, which explains why twice-weekly dosing works despite the 2-hour plasma half-life.
Thymosin Alpha 1 Benefits
- Thymosin Alpha 1 benefits center on immune modulation and T-cell restoration, with clinical evidence strongest in hepatitis B treatment.
- HBeAg seroconversion reached 30 to 40% versus 18% on placebo in hepatitis B patients treated for 6 to 12 months (PMC4688733, Phase III RCT).
- T-cell and NK cell activation without stimulant-like effects. Users report no subjective "high" or energy spike; confirmation requires bloodwork showing improved CD4/CD8 ratios and lymphocyte counts.
- AECOPD patients showed improved FEV1, better oxygenation, and shorter hospital stays across 39 RCTs enrolling 3,329 patients (meta-analysis 2024)[2].
- Post-viral recovery signal in ME/CFS communities. Responders report energy improvement within 24 to 48 hours. Ex vivo data (PMC10030336, n=10 PASC patients) confirmed decreased IL-6, decreased IFN-γ, and increased IL-10.
- Vaccine response improvement in elderly and immunocompromised populations, with community and clinical reports of stronger antibody titers when co-administered.
- Immune balancing as well as boosting. Tα1 upregulates regulatory T cells and modulates IDO expression, reducing autoimmune overshoot risk compared to pure immune stimulants.
Thymosin Alpha 1: Science vs Community Consensus
Well-established immunomodulator with 40+ years of clinical data.
Read the evidence (key study, limitations)
1.6 mg SC 2x/week for hepatitis B is the gold standard (Zadaxin label; approved in 35+ countries). Cancer adjuvant data emerging (NSCLC Phase II, HCC retrospective 2024–2025). TESTS Phase 3 sepsis trial (n=1,106)[3] failed primary 28-day mortality endpoint. COVID-19 benefit limited to severe/elderly subgroups in meta-analyses; highly heterogeneous (I²=90%). Long COVID evidence is ex vivo only (PMC10030336, n=10).
PMID 38308608: Dinetz/Lee 2024 narrative review, 30+ trials, 11,000+ subjects; PMC4688733: Hepatitis B Phase III RCT (Zadaxin vs placebo); PMID 39648386: AECOPD meta-analysis, 39 RCTs, 3,329 patients
TESTS Phase 3 sepsis trial (PMID 39814420) null result: HR 0.99, p=0.93. COVID-19 meta-analyses: I²=90% heterogeneity: conflicting results driven by study design differences. Long COVID dosing extrapolated from hepatitis B trials. No human longevity RCT. PMID 38308608 is a narrative review from a pro-compounding advocacy position, not a formal systematic meta-analysis.
Trusted immune primer for post-viral recovery, longevity, and seasonal immune support.
Read the reports (what users report 5, common issues 5)
No subjective "feel" limits enthusiasm but does not undermine trust among informed users. Widely used in long COVID/ME-CFS communities with anecdotal reports of T-cell exhaustion reversal.
- Reduced frequency and duration of infections over 8–12 week cycle
- Post-viral / long COVID T-cell exhaustion improvement (anecdotal; ex vivo mechanism supported by PMC10030336)
- Enhanced vaccine response in elderly and immunocompromised
- Immune normalization without stimulant-like subjective effects
- Improved energy in ME-CFS responders within 24–48 hours (subset of users)
- No immediate subjective signal: difficult to confirm benefit without bloodwork
- Access and cost disrupted by FDA 2023 compounding restriction (Category II); research-chemical market filled the gap
- TESTS Phase 3 null sepsis result (PMID 39814420) damaged "life-saving" narrative in community
- Autoimmune flare risk in Hashimoto's, MS, and lupus patients: documented in forum reports
- Some ME-CFS patients experience first-dose immune reaction (symptom exacerbation 24–48h)
Community dose (1600 mcg 2x/week) matches clinical standard well. However, community cycling (8–12 weeks on / 4 weeks off) has no clinical trial basis: all trials ran continuous protocols for 6–52 weeks without break periods. Community primary use cases (longevity, long COVID) lack RCT evidence and rely on mechanistic extrapolation from hepatitis B and immunology data.
Thymosin Alpha 1 Dosage Guide
Reconstitution math for a 10 mg vial with 2.0 mL bacteriostatic water: concentration is 5000 mcg/mL. Total volume is 200 units on a 100-unit insulin syringe (you'll need to refill). Each unit delivers 50 mcg. So 1600 mcg is 32 units, 750 mcg is 15 units.
For a 5 mg vial with 2.0 mL bacteriostatic water: concentration is 2500 mcg/mL. Each unit delivers 25 mcg. So 1600 mcg is 64 units, 750 mcg is 30 units.
The 10 mg vial is your better value. At 1600 mcg, it holds 6 full injections (10,000 / 1600 = 6.25), just over 3 weeks at twice weekly. A 5 mg vial holds 3.
Zinc matters. Tα1 requires zinc as a cofactor for T-cell and NK cell activation. Test RBC zinc before your protocol and supplement 15 to 30 mg zinc glycinate daily if deficient. Skipping this step is probably the most common beginner mistake.
Don't judge efficacy by how you feel. Tα1 produces no acute subjective signal. Get bloodwork (CBC with differential, CD4+/CD8+ counts) at baseline and week 8. That's the confirmation window.
Cycling Protocol
In hepatitis B clinical trials, Tα1 was administered at 1.6 mg subcutaneously twice weekly for 6-12 months. For general immune support, shorter courses of 8-12 weeks with a 4-week break are commonly used. Some protocols use continuous low-frequency dosing (1-2x/week) without cycling for chronic immune deficiency. No desensitization or tachyphylaxis has been documented in clinical use.
No receptor desensitization, tachyphylaxis, or antibody formation has been documented with TA1 in clinical trials, which ran continuous protocols for 6–52 weeks without break periods. Community cycling (8–12 weeks on / 4 weeks off) is cost-management-driven and community-derived, not pharmacologically required. Some ME-CFS patients report symptom return within 2–3 days of stopping, suggesting continuous dosing may be more appropriate for post-viral indications than cycling.
- Symptom return within 2–3 days of stopping (ME-CFS/long COVID users): suggests continuous dosing preferred over cycling for this population
- No loss-of-efficacy signal documented in multi-year continuous hepatitis B clinical trials
- No hormonal axis suppression, receptor downregulation, or tachyphylaxis mechanism identified
Or use the universal Peptide Calculator for any peptide.
Thymosin Alpha 1 Protocols by Goal
Expected: ALT normalization, HBV viral load reduction, HBeAg seroconversion ~30–40% vs ~18% placebo at 12 months (PMC4688733)
Monitor: HBV viral load, HBeAg/anti-HBe, ALT/AST at 3-month intervals; CBC with differential at baseline and month 3
How to Use Thymosin Alpha 1
- 1Reconstitute the lyophilized powder
Add 2.0 mL bacteriostatic water to a 10 mg vial (yields 5000 mcg/mL) or a 5 mg vial (yields 2500 mcg/mL). Swirl gently. Do not shake. Allow bubbles to settle before drawing.
- 2Draw your dose
For 1600 mcg from a 10 mg vial: draw 32 units on a 100-unit insulin syringe. From a 5 mg vial: draw 64 units. All three tiers use this 1600 mcg dose, the Zadaxin label dose (1.6 mg twice weekly).
- 3Choose an injection site
Subcutaneous injection in the abdomen (2 inches from navel), thigh, or upper arm. Use a 29 to 31 gauge insulin syringe, 0.5-inch needle. Rotate sites between injections.
- 4Inject subcutaneously
Pinch a fold of skin, insert the needle at a 45-degree angle, push the plunger slowly, and hold for 5 seconds before withdrawing.
- 5Timing and frequency
Inject twice weekly, spaced 3 to 4 days apart (Monday and Thursday is standard). Morning is preferred. No food or fasting requirements.
- 6Storage after reconstitution
Refrigerate at 2 to 8 degrees Celsius. Use reconstituted research-grade peptide within 7 days; pharmaceutical-grade (Zadaxin) is stable longer.
Alternative Routes
No published SC vs. IM pharmacokinetic comparison: COVID-19 protocols (PMC7747025) used the same mcg doses IM as the SC standard
IM is not the community or clinical standard for self-administration. SC is preferred for accessibility, reproducibility, and patient tolerance. No head-to-head bioavailability comparison exists.
Thymosin Alpha 1 Stacking Protocols
Works With
Complementary mechanisms: TA1 modulates adaptive immunity (T-cells, NK cells); BPC-157 addresses tissue repair, gut integrity, and local anti-inflammation. Combined for post-illness or post-surgery recovery.
BPC-157 250–500 mcg SC or IM daily + TA1 1600 mcg SC 2x/week; inject at separate sites
Different thymosin family with no immune pathway overlap: TB-500 = tissue repair via actin regulation; TA1 = adaptive immunity via T-cells. Stacked for post-illness recovery addressing both immune restoration and tissue healing. Naming confusion common: these are entirely distinct peptides.
TB-500 2–5 mg SC 2x/week + TA1 1600 mcg SC 2x/week; may share injection days or stagger
Acute infection stack: LL-37 provides direct antimicrobial/biofilm activity (innate immunity); TA1 rebuilds adaptive immune capacity (T-cells, NK cells). Used in long COVID protocols targeting both pathogen clearance and immune restoration. Monitor for additive immune activation: start LL-37 at low dose (50 mcg) when combining.
LL-37 50–100 mcg SC 2x/week + TA1 1600 mcg SC 2x/week; inject at separate sites on separate days
Longevity stack: Epithalon provides telomere-protective/epigenetic effects via pineal modulation; TA1 addresses age-related immune decline (immunosenescence). Common in anti-aging longevity protocols.
Epithalon 5–10 mg SC daily x10 days (annual course) timed before or concurrent with TA1 1600 mcg SC 2x/week
Avoid
Direct pharmacological antagonism: TA1 activates T-cell signaling pathways that calcineurin inhibitors suppress. In transplant recipients, TA1 immune activation risks acute graft rejection. Absolute contraindication in that population.
Do not combineBroad suppression of the immune pathways TA1 activates: co-administration negates TA1 efficacy. Concurrent systemic steroid use also typically indicates an underlying condition (autoimmune flare) where TA1 is itself contraindicated.
Do not combineTheoretical immune amplification risk outside oncologist-supervised settings. Note: emerging 2024–2025 oncology data (PMID 36871535, ASCO JCO 2024 e16226) suggests the two may add to each other's effect in cancer + reduced ICI-induced colitis: interaction is nuanced and context-dependent. Not for self-research concurrent use.
How much does Thymosin Alpha 1 cost?
Typical price
$6.42 to $9.00 per mg
Middle half of 79 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Thymosin Alpha 1 Side Effects
Organ transplant recipients on immunosuppressive therapy face the most serious risk. Tα1 activates the T-cell signaling pathways that calcineurin inhibitors (cyclosporine, tacrolimus) suppress. In that population, immune activation can trigger acute graft rejection. This is an absolute contraindication.
Autoimmune flare acceleration is documented in community and clinic reports. Hashimoto's patients have reported thyroid antibody titer spikes after starting Tα1. MS patients have reported flare acceleration. Lupus patients carrying antinuclear antibodies should check inflammatory markers (CRP, ESR, ANA) before starting and should not use Tα1 during active flare. The confusing part: autoimmune patients actually have lower serum thymosin alpha-1 levels [4]. That makes supplementation seem logical, but Tα1's immune-priming action feeds the same T-cell pathways driving the flare.
Published trial safety data across 11,000+ subjects shows a mild profile in non-autoimmune populations. Injection site redness and soreness occur in 5 to 18% of patients across trials. Transient fatigue occurs in 3 to 8%. Flu-like symptoms are rare and resolve within 24 to 48 hours. Myalgia reached 5% in one oncology loading-dose study.
ME/CFS and post-viral patients should know about the first-dose immune reaction. A subset experiences 24 to 48 hours of symptom exacerbation after the initial injection. This is an immune activation event, not an allergic reaction. Starting at 750 to 1000 mcg for the first two injections before escalating to 1600 mcg reduces this risk.
Interferon-alpha combinations (common in hepatitis protocols) can amplify flu-like side effects through additive immune stimulation. Stacking with other immune-stimulating peptides (LL-37, KPV) carries the same additive activation risk; space injections and start at low doses.
Contraindications: pregnancy or breastfeeding (insufficient safety data), known hypersensitivity to Tα1 or formulation components, organ transplant recipients on immunosuppression, active autoimmune diseases in flare, and children under 18.
When to seek medical attention: any autoimmune flare symptoms (joint pain, antibody titer rise, sustained fatigue spike), signs of graft rejection in transplant patients, high-grade fever, or allergic reaction (rash, difficulty breathing).
Common Issues & Solutions
No subjective signal: TA1 produces no acute "feel." Confirm benefit via bloodwork (CBC with differential, CD4+/CD8+ counts) at weeks 4 and 8. Most users require lab confirmation to verify efficacy: do not judge by subjective experience alone.
Autoimmune symptom worsening: Hashimoto's antibody titer spikes and MS/lupus flare acceleration documented in community and clinic reports. Pause immediately and check inflammatory markers (CRP, ESR, antinuclear antibodies). Do not restart until flare resolves and immunologist consulted.
Suspected blunted response: TA1 requires zinc as a cofactor for T-cell and NK cell activation. Test RBC zinc before protocol; supplement 15–30 mg zinc glycinate daily if deficient. Also confirm peptide purity (≥98% HPLC): research-grade impurities may reduce bioactivity.
ME-CFS / post-viral first-dose immune reaction: Subset of post-viral patients experience 24–48h symptom exacerbation after first injection: a known immune activation event, not allergy. Mitigate by starting at 750–1000 mcg for first 2 injections, then escalating to 1600 mcg.
Stopping too early with no benefit: Immune priming requires minimum 4–8 weeks. One to two injections will not produce measurable immune changes. Commit to the full 8-week cycle with end-of-cycle bloodwork before evaluating efficacy.
Ask AI about this page
Ask AI for a second opinion on Thymosin Alpha 1 dosing and side effects
Contraindications
- Pregnancy or breastfeeding: insufficient safety data in these populations
- Known hypersensitivity to thymosin alpha-1 or any formulation component
- Organ transplant recipients on immunosuppressive therapy: risk of graft rejection from immune activation
- Active autoimmune diseases in flare (e.g., lupus, rheumatoid arthritis): may worsen symptoms by stimulating immune activity
- Children under 18: not adequately studied in pediatric populations
Drug Interactions
- Immunosuppressants (cyclosporine, tacrolimus, corticosteroids): TA1 may counteract immunosuppressive effects; monitor closely
- Interferon-alpha: commonly used in combination for hepatitis; additive immune stimulation may increase flu-like side effects
- Other immune-stimulating peptides (LL-37, KPV): stacking may cause excessive immune activation; use with caution
- Checkpoint inhibitors (nivolumab, pembrolizumab): theoretical risk of amplified immune responses; no formal interaction studies
- Broad suppression of the immune pathways TA1 activates: co-administration negates TA1 efficacy. Concurrent systemic steroid use also typically indicates an underlying condition (autoimmune flare) where TA1 is itself contraindicated.
Product Quality
FDA compounding restriction (Category II, Sept 2023; removed Sept 2024; no final 503A rule as of October 2026: PCAC Dec 2024 recommended against 503A approval) has shifted most US users to research-chemical grade sources. FDA cited manufacturing impurity concerns and theoretical immunogenicity at high doses. Research-chemical TA1 lacks pharmaceutical-grade purity verification.
- A useful COA shows HPLC purity ≥98% and mass spectrometry (MS) identity confirmation: internal-only COAs prove little
- Verify 28-amino-acid sequence via MS: truncated or substituted sequences can appear identical on visual inspection
- Reconstituted research-grade peptide: use within 7 days refrigerated (conservative vs. 21 days for pharmaceutical-grade)
- International Zadaxin (genuine branded ampule form from approved markets) is highest purity option when accessible
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| CBC with differential (lymphocyte count) | Baseline and week 8 | Lymphocyte count: 1.0–4.8 × 10⁹/L; improvement from depleted baseline expected |
| CD4+ and CD8+ T-cell counts, CD4/CD8 ratio | Baseline and week 8 (specialty lab add-on) | CD4/CD8 ratio: 1.0–3.5; CD4+ >500/µL; improvement from depleted baseline expected |
| NK cell activity | Baseline and week 8 (specialized immunology lab) | Not listed |
| RBC zinc | Baseline (recommended pre-protocol) | 9.0–14.7 mg/L (RBC zinc reference range) |
| ALT / AST | Baseline and month 3 (hepatitis B patients) | ALT normalization target: <40 U/L |
| HBV viral load + HBeAg / anti-HBe | Baseline and every 3 months (hepatitis B patients only) | Not listed |
| Inflammatory markers (CRP, ESR, antinuclear antibodies) | Baseline in patients with personal or family history of autoimmune conditions | Not listed |
| T-cell exhaustion markers (PD-1, TIM-3 expression) | Baseline and week 8 (post-viral / long COVID use; requires specialized immunology lab) | Not listed |
Primary practical marker for immune activation; lymphocyte increase is the accessible proxy for T-cell modulation
Direct measure of T-cell modulation: the primary mechanism of TA1 action and primary endpoint in hepatitis B trials
NK cell cytotoxicity is a key TA1 efficacy endpoint in clinical immunology trials
TA1 requires zinc as a cofactor for T-cell and NK cell activation; deficiency may blunt response
Primary clinical endpoint for hepatitis B response monitoring
Primary efficacy endpoints for the Zadaxin-approved hepatitis B indication
Rule out active autoimmune flare before starting; monitor for worsening in Hashimoto's, MS, or lupus patients during cycle
Gold standard for confirming T-cell exhaustion reversal in post-viral/PASC context (PMC10030336)
Thymosin Alpha 1 Before and After
Treatment initiation. TA1 begins activating dendritic cells and priming T-cell responses. No noticeable clinical changes yet. Injection site irritation is possible but uncommon.
Early immune activation. T-cell subsets (CD4+, CD8+) begin to increase. NK cell activity starts to rise. Some users report improved energy and reduced frequency of minor infections.
Peak immune modulation. Measurable improvements in T-cell counts and function on bloodwork. Patients with hepatitis B may see ALT normalization and viral load reduction. Improved response to vaccinations if co-administered.
Sustained immune balancing. Continued improvements in immune markers. In hepatitis B trials, HBeAg seroconversion rates increased with extended treatment. Effects persist for weeks after discontinuation due to immune memory.
What to Expect
Week 1: Protocol initiation. Tα1 activates TLR2/TLR9 signaling on dendritic cells and the T-cell differentiation cascade begins. Nothing changes clinically. Injection site redness hits 5 to 18% of users across trials; transient fatigue runs 3 to 8%. ME/CFS patients may notice a minor energy fluctuation in the first 24 to 48 hours from first-dose immune activation.
Weeks 2 to 4: Early immune activation. CD4+ and CD8+ T-cell subsets begin maturation. NK cell cytotoxic activity starts climbing. Some users report reduced severity of minor infections in this window. ME/CFS responders may notice energy gains. Most people report nothing subjective. Transient flu-like symptoms are rare and resolve within 24 to 48 hours; myalgia reached 5% in one oncology loading-dose study.
Weeks 4 to 8: Peak immune modulation. Bloodwork starts showing measurable T-cell count and CD4/CD8 ratio improvements. Hepatitis B patients may see ALT normalization and viral load reduction. AECOPD data (39 RCTs, 3,329 patients)[2] confirmed improved FEV1 and oxygenation in this window. Vaccine co-administration shows improved antibody titers in elderly populations. Week 8 bloodwork is the confirmation point.
Weeks 8 to 12+: Sustained immune balancing. T-cell subset improvements continue. Hepatitis B patients see HBeAg seroconversion rates increase with extended treatment, peaking at 12 months post-treatment. Effects persist for weeks after stopping because of immune memory; no tachyphylaxis has been documented. Community cycles typically end here. ME/CFS users may notice symptom return within days of stopping, pointing toward continuous dosing for that population rather than cycling.
Detailed Timeline: Science vs Community
TLR2/TLR9 (and TLR3/TLR4) signaling activation on dendritic cells. Downstream T-cell differentiation cascade begins. No measurable clinical changes yet.
No acute subjective signal. Mild injection site redness possible. ME-CFS subset may note minor 24–48h energy fluctuation (first-dose immune activation).
CD4+ and CD8+ T-cell subsets begin maturation and differentiation. NK cell cytotoxic activity increasing. No clinical-level immune response detectable without specialized labs.
Some users report reduced severity of minor infections. ME-CFS responders may note energy improvement in this window. Most report nothing subjective.
Measurable improvements in T-cell counts and CD4/CD8 ratio on bloodwork. Hepatitis B patients: ALT normalization and HBV viral load reduction. Vaccine co-administration: enhanced antibody titers in elderly. AECOPD: ↑FEV1, ↑pO2, ↓hospital stay (PMID 39648386, 39 RCTs).
Reduced infection frequency becoming noticeable. Bloodwork showing improved lymphocyte count. Post-viral patients reporting sustained energy improvements. Week 8 bloodwork is the key confirmation window.
Continued T-cell subset improvements. Hepatitis B: HBeAg seroconversion increases with extended treatment; peak response at 12 months post-treatment. Effects persist weeks after discontinuation due to immune memory: no tachyphylaxis documented.
Community cycles typically end here. Infection frequency measurably reduced over cycle. ME-CFS users may report symptom return within days of stopping, suggesting continuous dosing requirement.
Pharmacokinetics
Source: Approximately 2 hours following subcutaneous injection, with blood levels returning to baseline within 24 hours (PMID 10027483)
Pharmacokinetics: Active Dose Over Time
t½ = ~2 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Thymosin Alpha 1 Legal?
Thymosin Alpha 1 is marketed as Zadaxin (SciClone Pharmaceuticals) and is approved as a prescription drug in over 35 countries for hepatitis B treatment and as an immune adjuvant. It is not FDA-approved in the United States.
The FDA designated TA1 as Category II under 503A/503B compounding rules in September 2023, restricting US compounding pharmacy access. That designation was removed in September 2024, but the final 503A determination remains pending. The PCAC committee in December 2024 recommended against 503A approval. FDA's Category 2 page (current as of April 22, 2026) lists Thymosin-alpha 1 (Ta1) among substances withdrawn by their nominators. FDA's May 14, 2026 503A list places it in no category. FDA's March 21, 2025 503B list has thymosin alpha-1 in Category 3, nominated without adequate support. No FDA rule on a 503A listing has followed.
TA1 is currently available in the US as a research chemical. It is not scheduled as a controlled substance. Athletes should note that immunomodulatory peptides may fall under WADA prohibited substance categories depending on interpretation; check current WADA guidelines before use in tested competition.
This content is for informational purposes only. Thymosin Alpha 1 is not approved by the FDA for any indication in the United States. Nothing on this page constitutes medical advice. Consult a licensed healthcare provider before starting any peptide protocol.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider Thymosin Alpha 1
- Individuals with chronic hepatitis B or C seeking immune-based treatment
- Patients with weakened or suppressed immune systems (immunodeficiency)
- Cancer patients undergoing chemotherapy who need immune support
- Older adults experiencing age-related immune decline (immunosenescence)
- People with recurrent viral infections or poor vaccine response
Related Peptides
What Changed for Thymosin Alpha 1
Peptide Schedule Research TeamReviewed Apr 7, 202617 Citations
References
- [1]Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials (Altern Ther Health Med 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis (J Coll Physicians Surg Pak 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial (Wu et al., BMJ 2025) (opens in a new tab)(n=1,106)PubMed (opens in a new tab)PubMed
- [4]Serum thymosin alpha-1 levels in patients with chronic inflammatory autoimmune diseases (Pica et al., Clin Exp Immunol 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Thymosin alpha-1 (Am J Health Syst Pharm 2001) (opens in a new tab)PubMed 11381492PubMed
- Zadaxin (thymosin alpha1) for the treatment of viral hepatitis (Expert Opin Investig Drugs 1999) (opens in a new tab)PubMed 15992078PubMed
- Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers (Int J Clin Pharmacol Ther 1998) (opens in a new tab)PubMed 10027483PubMed
- Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study (J Viral Hepat 1999) (opens in a new tab)PubMed 10607256PubMed
- Immune modulation with thymosin alpha 1 treatment (Vitam Horm 2016) (opens in a new tab)PubMed 27450734PubMed
- Thymosin alpha-1: reimagine its broader applications in the immuno-oncology era (Mao et al., Int Immunopharmacol 2023) (opens in a new tab)PubMed 36871535PubMed
- PMC4688733 (PMC4688733) (opens in a new tab)PubMed
- PMC10030336 (PMC10030336) (opens in a new tab)PubMed
- PMC7747025 (PMC7747025) (opens in a new tab)PubMed
- PMC12208829 (PMC12208829) (opens in a new tab)PubMed
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, content current as of April 22, 2026) (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503A, categories (updated May 14, 2026) (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503B, categories (updated March 21, 2025) (opens in a new tab)Review
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Thymosin Alpha 1?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Moderate. Community mentions on Reddit: Moderate (CFS, post-viral, longevity communities).
400 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.